AGBL3 and rheumatoid arthritis: In addition, further understanding of the epigenetic differences between At-Risk and anti-CCP3(−) controls, and integration with emerging data suggesting the presence of different endotypes in the pre-RA period should inform regarding the various pathways18, perhaps driven by unique mucosal/systemic immune site interactions or the differential influence of environmental factors on these early steps33.